EUVIMEDEUVIMED entdecken
Crossref

Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease

Sean T Campbell iD

Clinical Chemistry · 2024

DOI: 10.1093/clinchem/hvae038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2024. Verfasst von Sean T Campbell. Beteiligte Einrichtung: Pathology, Montefiore Medical Center, Bronx, NY, United States. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, CRISPR-Cas Systems, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 2 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On December 8, 2023 the United States Food and Drug Administration (FDA) made a historic decision to approve the first drug harnessing clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing technology, CASGEVY™ (exagamglogene autotemcel) (1). To make things even more historic, this was an approval for a biologic targeting sickle cell disease (SCD), the most common inherited blood disease worldwide, affecting more than 100 000 people in the United States alone. Prior to this announcement, only 3 pharmaceutical treatments had been approved for SCD: hydroxyurea, Oxbryta® (voxelotor), and Endari (L-glutamine). The only nonpharmaceutical treatments available are red blood cell transfusion and allogeneic bone marrow transplantation. Into this treatment void came Casgevy, the first FDA-approved treatment involving the use of CRISPR/Cas9. This treatment works by mobilizing a patient’s stem cells for peripheral blood collection, and then editing the patient’s stem cell DNA to increase fetal hemoglobin production. The gene editing targets the B-cell lymphoma/leukemia 11A (BCL11A) gene, which normally suppresses the production of fetal hemoglobin (HbF). Thus, targeting this gene results in the patient’s edited cells generating high levels of HbF. HbF is a natural hemoglobin typically produced during fetal development and up to a year after birth. The newly produced HbF interferes with the aggregation of hemoglobin S, stopping cells from sickling and thus preventing the worst effects of SCD. As Casgevy changes the hemoglobin makeup of the patient’s blood, this may have implications for hemoglobin fractionation assays that are used for the diagnosis and monitoring of patients with SCD and other hemoglobinopathies. The monitoring will be relatively straightforward and similar to monitoring employed with SCD patients on hydroxyurea, a treatment that also causes increased HbF. However, Casgevy should not cause increases in red blood cell size that are common in hydroxyurea-treated patients. Patients in the latest Casgevy trial were reported to have HbF percentages of >40% after 40 months (2). Casgevy may prove a challenge for the laboratory diagnosis of new patients, and laboratories providing hemoglobinopathy services should be aware of these novel therapies and their impact on diagnostic testing. The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. Upon manuscript submission, all authors completed the author disclosure form. None declared. S.T. Campbell has received research support, including salary support, from Global Blood Therapeutics (a subsidiary of Pfizer) and Sebia A.E. Additionally, he has received speaking honoraria from Sebia A.E. and Diagnostica Stago, travel funding from Bio-Rad Laboratories, and is Associate Editor for The Journal of Applied Laboratory Medicine, ADLM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellCRISPR-Cas SystemsGene EditingGenetic TherapyHumansUnited StatesUnited States Food and Drug Administration

Autor:innen und Institutionen

  • Pathology, Montefiore Medical Center, Bronx, NY, United States.

ORCID-Profile: Sean T Campbell

Zitieren

APA

Campbell, S. T. (2024). Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvae038

Vancouver

Campbell ST. Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease. Clinical Chemistry. 2024. doi:10.1093/clinchem/hvae038

BibTeX
@article{Campbell2024,
  author = {Campbell, Sean T},
  title = {Approval of the First CRISPR-Cas9 Gene Editing Therapy for Sickle Cell Disease},
  journal = {Clinical Chemistry},
  year = {2024},
  doi = {10.1093/clinchem/hvae038}
}
Kostenlos starten →